Catalyst Capital Advisors LLC Sells 74 Shares of Stryker Corporation $SYK

Catalyst Capital Advisors LLC cut its stake in Stryker Corporation (NYSE:SYK) by 14.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 453 shares of the medical technology company’s stock after selling 74 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in Stryker were worth $179,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker in the second quarter worth approximately $26,000. Sachetta LLC grew its stake in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the period. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the first quarter worth approximately $32,000. Ridgewood Investments LLC grew its stake in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 30 shares during the period. Finally, Ransom Advisory Ltd bought a new stake in Stryker during the first quarter valued at approximately $37,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK opened at $381.86 on Friday. The firm has a market cap of $145.99 billion, a P/E ratio of 50.58, a PEG ratio of 2.76 and a beta of 0.94. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a 50 day simple moving average of $379.84 and a two-hundred day simple moving average of $379.73. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Analyst Ratings Changes

Several brokerages recently issued reports on SYK. Rothschild & Co Redburn began coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price for the company. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a research report on Friday. Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, Truist Financial cut their target price on shares of Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research report on Wednesday, October 15th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $432.24.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.